HEMOSTATIC FACTORS AND REPLACEMENT OF MAJOR BLOOD-LOSS WITH PLASMA-POOR RED-CELL CONCENTRATES

被引:511
作者
HIIPPALA, ST
MYLLYLA, GJ
VAHTERA, EM
机构
[1] HELSINKI UNIV,CENT HOSP,DEPT ANESTHESIOL,HELSINKI,FINLAND
[2] FINNISH RED CROSS & BLOOD TRANSFUS SERV,SF-00310 HELSINKI,FINLAND
关键词
D O I
10.1097/00000539-199508000-00026
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
The purpose of this study was to assess the change of platelet and fibrinogen concentrations and the change of activities of prothrombin and factors V and VII when major surgical blood loss was replaced with plasma-poor red cell concentrates (RCCs) and colloid plasma substitutes. Sixty patients were studied. The average blood loss was 65% +/- 41% of the calculated blood volume (CBV). Blood loss was monitored carefully and replaced without delay to ensure stable blood volume. Blood samples were obtained at the induction of anesthesia and at the end of the recovery room period, or before the patient was given fresh frozen plasma. In addition, a platelet count was determined after each 20% blood loss. The results were converted to relative values, and simple Linear regression with logarithmic transformation was applied. The initial platelet concentration was 257 +/- 89 x 10(3)/mm(3) and the extrapolation of the regression line intercepted the critical level of 50 x 10(3)/mm(3) at 230% (confidence interval 169%-294%) blood loss. The initial fibrinogen concentration was 3.7 +/- 1.1 g/L and the hemostatically significant level of 1.0 g/L was already reached at 142% (117%-169%) blood loss (r(2) = 0.90). Activities of prothrombin and coagulation factors V and VII reached their critical levels at 201% (160%-244%), 229% (167%-300%), and 236% (198%-277%) blood loss, respectively. We conclude that deficiency of fibrinogen develops earlier than any other hemostatic abnormality when plasma-poor RCCs are used for the replacement of major blood loss.
引用
收藏
页码:360 / 365
页数:6
相关论文
共 18 条
[1]   CLOTTING FACTOR LEVELS AND THE RISK OF DIFFUSE MICROVASCULAR BLEEDING IN THE MASSIVELY TRANSFUSED PATIENT [J].
CIAVARELLA, D ;
REED, RL ;
COUNTS, RB ;
BARON, L ;
PAVLIN, E ;
HEIMBACH, DM ;
CARRICO, CJ .
BRITISH JOURNAL OF HAEMATOLOGY, 1987, 67 (03) :365-368
[2]   HEMOSTASIS IN MASSIVELY TRANSFUSED TRAUMA PATIENTS [J].
COUNTS, RB ;
HAISCH, C ;
SIMON, TL ;
MAXWELL, NG ;
HEIMBACH, DM ;
CARRICO, CJ .
ANNALS OF SURGERY, 1979, 190 (01) :91-99
[3]   PERIOPERATIVE HEMOTHERAPY .1. INDICATIONS FOR BLOOD COMPONENT TRANSFUSION [J].
CROSBY, ET .
CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE, 1992, 39 (07) :695-707
[4]  
Fakhry SM, 1994, MASSIVE TRANSFUSION, P17
[5]   OPTIMAL USE OF BLOOD COMPONENTS [J].
GRAVLEE, GP .
INTERNATIONAL ANESTHESIOLOGY CLINICS, 1990, 28 (04) :216-222
[6]  
HOGMAN CF, 1983, VOX SANG, V45, P217
[7]   LABORATORY HEMOSTATIC ABNORMALITIES IN MASSIVELY TRANSFUSED PATIENTS GIVEN RED-BLOOD-CELLS AND CRYSTALLOID [J].
LESLIE, SD ;
TOY, PTCY .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1991, 96 (06) :770-773
[8]   COAGULATION DEFECTS ASSOCIATED WITH MASSIVE BLOOD TRANSFUSIONS [J].
MILLER, RD ;
ROBBINS, TO ;
TONG, MJ .
ANNALS OF SURGERY, 1971, 174 (05) :794-&
[9]   COAGULATION AND PACKED RED-BLOOD-CELL TRANSFUSIONS [J].
MILLER, RD .
ANESTHESIA AND ANALGESIA, 1995, 80 (02) :215-216
[10]  
MILLER RD, 1990, ANESTHESIA, P1467